DGX vs LH
Quest Diagnostics and Labcorp, both Healthcare
Quest Diagnostics is the larger company at $22B against $21B. On trailing earnings DGX is the cheaper of the two at a P/E of 27.1 against 29.7, a gap that is only a bargain if the two are growing at similar rates. Over the past year DGX returned +44% against +30% for LH. Ryufin's sector-relative Smart Score puts LH ahead, 7/10 against 6/10.
| Figure | DGX | LH |
|---|---|---|
| Last close | $245 | $336 |
| Market cap | $22B | $21B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.1 | 29.7 |
| Dividend yield | n/a | 0.9% |
| 1-year return | +44% | +30% |
| 5-year return | +90% | +39% |
| Ryufin Smart Scoresector-relative, 1–10 | 6/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Quest Diagnostics
Revenue of $2.9B in Q1 2026, net income $252M. Its largest reported line is Diagnostic Information Services Business, 98% of the disclosed total.
Labcorp
Revenue of $3.5B in Q1 2026, net income $278M. Its largest reported line is Diagnostics, 78% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.